The results of long-term
use of Wobenzym in complex management of Behcet's disease
Kartvelishvili E., Shalamberidze L.,
Torondjadze M. The results of long-term use of Wobenzym in complex
management of Behcet's disease. International congress "Advances in
Immunology and Allergology at the Treshold of the XXI Century" May
3-6, 2000, Eilat, Israel. Czech abstract
Center of Rheumatology, Tbilisi, Georgia
Twenty patients (13 males and 7 females) with the confirmed diagnosis of Behcet's disease were followed-up. Average age of the patients was 41.27±2.96. The diagnosis was verified following the international criteria which were worked out by the International Study Group for Behcet's Disease (1990). As a rule each patient had recurrent aphthous stomatitis and 2 or 3 of the following four criteria: recurrent ulcers of genital organs, eye and skin lesions, positive "pathergy" test.
The patients were administered Prednisolone at a dose of 10-15 mg/day, Azathioprine (100 mg/day), non-steroid antiinflammation medicines, antiaggregating drugs etc. However because of the absence of the expressed therapeutic effect after 1-1.5 months of the treatment Wobenzym (Mucos Pharma, Germany) in the dose of 7 tablets three times a day was added to the scheme. Favourable dynamics of clinical manifestations, inflammatory and immune activities were observed 0.5-1 month after introduction of Wobenzym. Significant decrease in the level of circulating immune complexes and cryoglobulins is noteworthy. Positive results (90.0%) combined with the absence of side effects and possibility to decrease the Prednisolone doses are significant success in the management of this severe disease.